Xeris Biopharma Holdings (XERS) Non-Current Assets (2020 - 2026)

Xeris Biopharma Holdings' Non-Current Assets history runs 7 years deep, the most recent figure standing at $140.3 million for Q1 2026.

• Quarterly Non-Current Assets fell 7.65% year-over-year to $140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $578.8 million (down 7.69% YoY) and the FY2025 annual result came in at $143.2 million, down 7.84% from the prior year.
• Non-Current Assets was $140.3 million for Q1 2026 at Xeris Biopharma Holdings, down from $143.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $173.0 million in Q2 2023 and bottomed at $140.3 million in Q1 2026.
• A 5-year average of $156.7 million and a median of $157.4 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets soared 2135.57% — and 2025, when it dropped 7.84%.
• Xeris Biopharma Holdings' Non-Current Assets stood at $157.7 million in 2022, then gained by 5.47% to $166.3 million in 2023, then fell by 6.58% to $155.4 million in 2024, then declined by 7.84% to $143.2 million in 2025, then slipped by 2.01% to $140.3 million in 2026.
• Business Quant data shows XERS's Non-Current Assets at $140.3 million in Q1 2026, $143.2 million in Q4 2025, and $146.2 million in Q3 2025.